Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care
Authors
Keywords
-
Journal
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-12
DOI
10.1007/s40618-021-01501-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
- (2020) Lars Johansson et al. DIABETES OBESITY & METABOLISM
- Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications
- (2020) Stefano Ciardullo et al. BMJ Open Diabetes Research & Care
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Comparison of the effects of three kinds of glucose‐lowering drugs on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open‐label, three‐arm, active control study
- (2020) Tomoe Kinoshita et al. Journal of Diabetes Investigation
- A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
- (2020) John A. Dougherty et al. ANNALS OF PHARMACOTHERAPY
- Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future
- (2020) Sergio Rodríguez Tajes et al. JOURNAL OF HEPATOLOGY
- Non‐invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study
- (2020) Sheila M. Grecian et al. LIVER INTERNATIONAL
- Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005–2016
- (2020) Stefano Ciardullo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
- (2019) Amalia Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study
- (2018) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients
- (2017) Amandeep Singh et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes)
- (2017) G.P. Fadini et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies
- (2015) Wenjuan Tang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- NAFLD: A multisystem disease
- (2015) Christopher D. Byrne et al. JOURNAL OF HEPATOLOGY
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
- (2014) L. Fedchuk et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
- (2013) Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
- Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy
- (2011) Boris Guiu et al. EUROPEAN RADIOLOGY
- Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease
- (2009) Jeong-Hoon Lee et al. DIGESTIVE AND LIVER DISEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started